RxDoctor Payments DataLook up a doctor →

Osama Hamdy

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1902841596

Payments from drug & device makers

$1,067,889in general payments, 2019–2025

Across 1,191 payments — averaging $896.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$457K
  • Eli Lilly$439K
  • Sanofi-aventis U.S. LLC$80K
  • Mannkind Corporation$55K
  • AstraZeneca$10K
  • Upjohn US 1 LLC$6K
  • plus $21K from 8 others
$35,798in research payments, 2019–2025

Across 4 payments — averaging $8949.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$36K
  • Novo Nordisk$48

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,124$457,094
Eli Lilly22$439,237
Sanofi-aventis U.S. LLC17$79,670
Mannkind Corporation5$54,952
AstraZeneca1$9,765
Upjohn US 1 LLC1$6,400
Takeda1$5,000
Gilead10$3,936
Novo Nordisk3$3,915
BD1$3,750
Insulet Corporation2$2,099
Mylan Inc.1$2,000
Abbott2$56
Inspire Medical Systems, Inc.1$15

How this compares

$1,067,889 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$26,528
Medicare patients
144
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →